Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Bullboard Posts
Comment by rjc7on Feb 18, 2016 10:23am
84 Views
Post# 24570344

RE:RE:RE:wtf y isnt this tanking

RE:RE:RE:wtf y isnt this tankingI can't remember them ever giving guidance vis-a-vis anticipated revenues within a Q before. 

"While there was abnormal weakness in the first quarter, we expect strong performance over the rest of the year based on indicated customer demand, leading us to project record sales for the current fiscal year. Thus far, sales for the second quarter are in line with such full-year expectations." 

As well regarding Kinlytic:

The Company reports that discussions continue with a group of stakeholders interested in working with the Company to re-launch Kinlytic in the U.S., Canada and international markets. Meaningful lead committments have been made , subject to securing the balance of funding. 
Bullboard Posts